OverviewSuggest Edit

MiMedx Group a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The Company’s proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization.

TypePublic
Founded2008
HQMarietta, GA, US
Websitemimedx.com
Employee Ratings3.2
Overall CultureB+

Latest Updates

Employees (est.) (Dec 2019)696(-7%)
Job Openings33
Revenue (FY, 2020)$248.2 M(-17%)
Share Price (Sept 2021)$6.3(+2%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at MiMedx Group

Timothy R. Wright

Timothy R. Wright

Chief Executive Officer, Board Member
Mark P. Graves

Mark P. Graves

Chief Compliance Officer
Rohit Kashyap

Rohit Kashyap

Executive Vice President and Chief Commercial Officer
Thomas J. Koob

Thomas J. Koob

Chief Scientific Officer
Robert B. Stein

Robert B. Stein

Executive Vice President, Research and Development
Show more

MiMedx Group Office Locations

MiMedx Group has an office in Marietta
Marietta, GA, US (HQ)
1775 W Oak Commons Ct
Show all (1)

MiMedx Group Financials and Metrics

MiMedx Group Revenue

Embed Graph
View revenue for all periods
MiMedx Group's revenue was reported to be $248.23 m in FY, 2020
USD

Revenue (FY, 2020)

248.2m

Gross profit (FY, 2020)

208.9m

Gross profit margin (FY, 2020), %

84.2%

Net income (FY, 2020)

(49.3m)

EBIT (FY, 2020)

(45.4m)

Market capitalization (23-Sept-2021)

689.6m

Closing stock price (23-Sept-2021)

6.3

Cash (31-Mar-2021)

84.7m

EV

652.7m
MiMedx Group's current market capitalization is $689.6 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2018FY, 2019FY, 2020

Revenue

7.8m27.1m59.2m118.2m187.3m245.0m359.1m299.3m248.2m

Revenue growth, %

100%58%31%

Cost of goods sold

3.2m5.2m9.3m12.7m20.2m32.4m36.4m43.1m39.3m

Gross profit

4.6m21.9m49.9m105.6m167.1m212.6m322.7m256.2m208.9m
USDQ2, 2011

Financial Leverage

1.9 x
Show all financial metrics

MiMedx Group Operating Metrics

FY, 2016

Patent Applications

110

Patents (US)

92
Show all operating metrics

MiMedx Group Revenue Breakdown

Embed Graph

MiMedx Group revenue breakdown by business segment: 75.1% from Wound Care and 24.9% from Surgical, Sports Medicine & Orthopedics (SSO)

MiMedx Group Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

MiMedx Group Online and Social Media Presence

Embed Graph

MiMedx Group Company Culture

  • Overall Culture

    B+

    74/100

  • CEO Rating

    C+

    67/100

  • Compensation

    A+

    89/100

Learn more on Comparably

MiMedx Group News and Updates

Lucrative Regions for Biofilms Treatment Market 2020 to 2027 | Mimedx Group, Organogenesis Holdings, Smith and Nephew, Coloplast A/S

The biofilms treatment market was valued at US$ 1,590.31 million in 2019 and is projected to reach US$ 2,825.80 million by 2027; it is expected to grow at a CAGR of 7.5% during 2020–2027. Posted via Industry Today. Follow us on Twitter @IndustryToday

Schubert Jonckheer & Kolbe LLP Launches Investigation into Possible Breaches of Fiduciary Duty by MiMedx Group, Inc.'s Directors and Officers

SAN FRANCISCO, Aug. 1, 2018 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating whether certain directors and officers of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ:MDXG), a biopharmaceutical company, breached their fiduciary duties by causing the Company to engage ...

MiMedx Group Blogs

MiMedx Announces First Quarter 2021 Financial and Operating Results

First Quarter Net Sales of $60.0 Million Advancing Innovative Late-Stage Musculoskeletal Pipeline with Data Readouts Expected in Q3 2021 Company to Host Conference Call on April 29, 2021 at 8:30 AM ET MARIETTA, Ga., April 28, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc.

MiMedx Confirms Receipt of Director Nominations from Prescience Point Capital Management

No Shareholder Action Required at This Time MARIETTA, Ga., April 16, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing birth tissue as a platform for regenerative medicine, today confirmed that Prescience Point Capital Management

MiMedx to Host Fourth Quarter and Full Year 2020 Operating and Financial Results Conference Call on March 9

MARIETTA, Ga., March 02, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that it will report financial results for the fourth quarter and full year ended December

Reminder: MiMedx to Present at the 39th Annual J.P. Morgan Healthcare Conference

MARIETTA, Ga., Jan. 06, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M.

Jack Howarth, Senior Vice President, Investor Relations

Jack Howarth, Senior Vice President, Investor Relations John.Bissaillo… Tue, 12/01/2020 - 09:36 Jack Howarth Senior Vice President, Investor Relations Jack Howarth joined MiMedx in December 2020. Prior to joining the Company, Mr. Howarth served as Vice President,…

Cato T. Laurencin, M.D., Ph.D.

Cato T. Laurencin, M.D., Ph.D. John.Bissaillo… Wed, 11/25/2020 - 14:45 Cato T. Laurencin, M.D., Ph.D. Dr. Laurencin currently serves the Albert and Wilda Van Dusen Distinguished Endowed Professor of Orthopaedic Surgery at the University of Connecticut, and is one of two designated …
Show more

MiMedx Group Frequently Asked Questions

  • When was MiMedx Group founded?

    MiMedx Group was founded in 2008.

  • Who are MiMedx Group key executives?

    MiMedx Group's key executives are Timothy R. Wright, Mark P. Graves and Rohit Kashyap.

  • How many employees does MiMedx Group have?

    MiMedx Group has 696 employees.

  • What is MiMedx Group revenue?

    Latest MiMedx Group annual revenue is $248.2 m.

  • What is MiMedx Group revenue per employee?

    Latest MiMedx Group revenue per employee is $356.7 k.

  • Who are MiMedx Group competitors?

    Competitors of MiMedx Group include TissueTech, Verus Healthcare and Launch Diagnostics.

  • Where is MiMedx Group headquarters?

    MiMedx Group headquarters is located at 1775 W Oak Commons Ct, Marietta.

  • Where are MiMedx Group offices?

    MiMedx Group has an office in Marietta.

  • How many offices does MiMedx Group have?

    MiMedx Group has 1 office.